pSivida, a developer of sustained release drug delivery products, has entered into an agreement with a biopharmaceutical company for the evaluation of its Tethadur protein/antibody delivery technology.
Designed for use in the field of ophthalmology, the Tethadur delivery technology uses injectable, bioerodible, nanostructured, porous BioSilicon material to deliver large biologic molecules including proteins, antibodies and peptides.
pSivida said nanotechnology is used for manufacturing the sizes of the pores in the BioSilicon material to accommodate specific protein, peptide or antibody molecules that are then released on a sustained basis over time as the material bioerodes.
pSivida president and CEO Paul Ashton said the commercial agreement for Tethadur, based on BioSilicon, is the company’s second key technology platform, following three approved products utilizing its Durasert technology platform.
"A sustained delivery system for these types of molecules would offer a significant clinical advance in the ophthalmic area where injections of protein based drugs into the eye every one or two months are sometimes required," Ashton added.